Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

40%

2 of 5 completed trials have results

Key Signals

1 recruiting2 with results

Enrollment Performance

Analytics

Phase 2

4(57.1%)

N/A

2(28.6%)

Phase 1

1(14.3%)

7Total

Phase 2(4)

N/A(2)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT05030129Phase 2Completed

ERG/5-HTP in Fragile X Syndrome (FXS)

Role: collaborator

NCT06279858Not ApplicableRecruiting

Probiotic Intervention for Microbiome Modifications and Clinical Improvements in Fragile X Syndrome

Role: collaborator

NCT03722290Phase 2Completed

Metformin in Children and Adults With Fragile X Syndrome

Role: collaborator

NCT04141163Phase 1Unknown

Metformin in Patients With Fragile X

Role: collaborator

NCT02680379Phase 2Completed

Combined Treatment of Minocycline and Lovastatin to Treat Individuals With Fragile X Syndrome

Role: collaborator

NCT00858689Not ApplicableCompleted

Add-on Pilot Trial of Minocycline to Treat Fragile X Syndrome

Role: lead

NCT00054730Phase 2Completed

Effects of CX516 on Functioning in Fragile X Syndrome and Autism

Role: collaborator

All 7 trials loaded